High-Risk Pathogens in Immunocompromised Adults
Immunocompromised adults face three primary pathogen categories requiring prophylaxis: Pneumocystis jirovecii, invasive fungal infections (particularly Aspergillus), and reactivation of latent viral infections (HSV and hepatitis B). 1
Bacterial Pathogens
The depth and duration of neutropenia directly determines bacterial infection risk. For patients with profound, protracted neutropenia (ANC <500 cells/μL expected >7 days), fluoroquinolone prophylaxis is indicated 1. Cefpodoxime serves as an alternative for fluoroquinolone-intolerant patients 1.
Key Risk Factors Beyond Neutropenia:
- Impaired mucocutaneous barriers (catheters, mucositis)
- Metabolic perturbations (diabetes, uremia)
- Graft-versus-host disease
- Microbiome disruption 1
Fungal Pathogens
Invasive Candidiasis vs. Invasive Mold Infections
Antifungal prophylaxis with oral triazoles or parenteral echinocandins is mandatory for patients with profound, protracted neutropenia and grade III-IV mucositis 1. This applies primarily to:
- AML/MDS patients during chemotherapy
- HSCT recipients
- NOT routinely indicated for solid tumor patients 1
Critical distinction: Fluconazole covers yeast (Candida) but NOT molds. When invasive aspergillosis risk exceeds 6% (AML/MDS patients, late-stage post-allogeneic HSCT, GVHD), use mold-active triazoles (posaconazole, voriconazole, or isavuconazole) 1.
Pneumocystis jirovecii
TMP-SMX prophylaxis is strongly recommended when P. jirovecii pneumonia risk exceeds 3.5%, specifically for patients receiving:
- ≥20 mg prednisone equivalents daily for ≥1 month
- Purine analog-based chemotherapy 1
For sulfonamide-allergic patients: dapsone, aerosolized pentamidine, or atovaquone 1.
Viral Pathogens
Herpes Simplex Virus
All HSV-seropositive patients undergoing allogeneic HSCT or leukemia induction require nucleoside analog prophylaxis (acyclovir) 1. This is a strong, evidence-based recommendation with high-quality evidence.
Hepatitis B Virus
Nucleoside reverse transcription inhibitors (entecavir or tenofovir) are mandatory for high-risk HBV reactivation patients 1. This includes those receiving intensive chemotherapy or anti-CD20 monoclonal antibodies.
Respiratory Viruses
Annual inactivated influenza vaccination is required for all patients receiving chemotherapy, plus all household contacts and healthcare providers 1. Recent evidence demonstrates RSV causes substantial morbidity in immunocompromised adults, with hospitalization rates of 37.5-87.5% in lung transplant recipients and 30.3-83.9% in stem cell transplant recipients 2.
Environmental and Transmission-Based Precautions
Mandatory interventions include:
Hand hygiene and respiratory hygiene/cough etiquette by all healthcare workers (strong recommendation) 1
Neutropenic patients must avoid:
- Construction/demolition sites
- Intensive soil exposure (gardening, digging)
- Household renovation during neutropenia 1
HEPA filtration and positive pressure rooms for highest-risk populations (HSCT recipients, severe neutropenia), though resource-intensive 3
Universal masking shows emerging support for reducing respiratory viral infections 3
Critical Caveat
Antibacterial and antifungal prophylaxis are NOT indicated when colony-stimulating factors (CSF) effectively reduce neutropenia depth and duration 1. This represents a common pitfall—prophylaxis decisions must account for CSF use.
Vaccination Strategy
Beyond influenza, follow IDSA guidelines for vaccination of immunosuppressed hosts 1, 4, recognizing that live vaccines are generally contraindicated but inactivated vaccines remain essential despite potentially reduced immunogenicity.